nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—CYP2C19—prostate cancer	0.137	0.611	CbGaD
Vismodegib—CYP3A4—prostate cancer	0.0874	0.389	CbGaD
Vismodegib—ORM1—Abiraterone—prostate cancer	0.0496	0.0967	CbGbCtD
Vismodegib—ABCG2—Cabazitaxel—prostate cancer	0.0224	0.0437	CbGbCtD
Vismodegib—ABCG2—Estrone—prostate cancer	0.0219	0.0427	CbGbCtD
Vismodegib—ALB—Abiraterone—prostate cancer	0.0209	0.0407	CbGbCtD
Vismodegib—CYP2C8—Nilutamide—prostate cancer	0.0195	0.038	CbGbCtD
Vismodegib—CYP2C19—Bicalutamide—prostate cancer	0.0163	0.0318	CbGbCtD
Vismodegib—CYP2C19—Nilutamide—prostate cancer	0.0163	0.0318	CbGbCtD
Vismodegib—CYP2C8—Abiraterone—prostate cancer	0.0161	0.0314	CbGbCtD
Vismodegib—ALB—Estrone—prostate cancer	0.0151	0.0294	CbGbCtD
Vismodegib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.015	0.0293	CbGbCtD
Vismodegib—ABCG2—Conjugated Estrogens—prostate cancer	0.0143	0.0279	CbGbCtD
Vismodegib—CYP2C9—Bicalutamide—prostate cancer	0.0136	0.0265	CbGbCtD
Vismodegib—CYP2C9—Nilutamide—prostate cancer	0.0136	0.0265	CbGbCtD
Vismodegib—CYP2C19—Flutamide—prostate cancer	0.0135	0.0264	CbGbCtD
Vismodegib—ABCG2—Mitoxantrone—prostate cancer	0.013	0.0254	CbGbCtD
Vismodegib—ABCG2—Estradiol—prostate cancer	0.0126	0.0245	CbGbCtD
Vismodegib—ABCB1—Estramustine—prostate cancer	0.0122	0.0239	CbGbCtD
Vismodegib—CYP2C8—Cabazitaxel—prostate cancer	0.0119	0.0233	CbGbCtD
Vismodegib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0104	0.0203	CbGbCtD
Vismodegib—ALB—Estradiol—prostate cancer	0.00866	0.0169	CbGbCtD
Vismodegib—ABCG2—Etoposide—prostate cancer	0.0082	0.016	CbGbCtD
Vismodegib—CYP2C9—Estrone—prostate cancer	0.00813	0.0159	CbGbCtD
Vismodegib—ABCB1—Cabazitaxel—prostate cancer	0.00807	0.0157	CbGbCtD
Vismodegib—CYP3A4—Bicalutamide—prostate cancer	0.00789	0.0154	CbGbCtD
Vismodegib—ABCB1—Estrone—prostate cancer	0.00789	0.0154	CbGbCtD
Vismodegib—ABCG2—Docetaxel—prostate cancer	0.00751	0.0146	CbGbCtD
Vismodegib—ALB—Prednisone—prostate cancer	0.00745	0.0145	CbGbCtD
Vismodegib—CYP3A4—Estramustine—prostate cancer	0.00733	0.0143	CbGbCtD
Vismodegib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00703	0.0137	CbGbCtD
Vismodegib—CYP2C8—Estradiol—prostate cancer	0.00669	0.0131	CbGbCtD
Vismodegib—CYP3A4—Flutamide—prostate cancer	0.00654	0.0128	CbGbCtD
Vismodegib—CYP3A4—Abiraterone—prostate cancer	0.00654	0.0128	CbGbCtD
Vismodegib—CYP2C9—Capecitabine—prostate cancer	0.00616	0.012	CbGbCtD
Vismodegib—CYP2C19—Estradiol—prostate cancer	0.00561	0.011	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—prostate cancer	0.0056	0.0109	CbGbCtD
Vismodegib—ABCB1—Conjugated Estrogens—prostate cancer	0.00516	0.0101	CbGbCtD
Vismodegib—CYP3A4—Cabazitaxel—prostate cancer	0.00484	0.00943	CbGbCtD
Vismodegib—CYP2C19—Prednisone—prostate cancer	0.00483	0.00942	CbGbCtD
Vismodegib—CYP3A4—Estrone—prostate cancer	0.00473	0.00922	CbGbCtD
Vismodegib—ABCB1—Mitoxantrone—prostate cancer	0.00469	0.00915	CbGbCtD
Vismodegib—CYP2C9—Estradiol—prostate cancer	0.00467	0.00911	CbGbCtD
Vismodegib—ABCB1—Estradiol—prostate cancer	0.00453	0.00884	CbGbCtD
Vismodegib—CYP2C8—Etoposide—prostate cancer	0.00437	0.00853	CbGbCtD
Vismodegib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00421	0.00822	CbGbCtD
Vismodegib—ABCB1—Prednisone—prostate cancer	0.0039	0.0076	CbGbCtD
Vismodegib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00309	0.00603	CbGbCtD
Vismodegib—ABCB1—Etoposide—prostate cancer	0.00296	0.00577	CbGbCtD
Vismodegib—SHH—epithelium—prostate cancer	0.00289	0.0933	CbGeAlD
Vismodegib—CYP3A4—Mitoxantrone—prostate cancer	0.00281	0.00548	CbGbCtD
Vismodegib—SMO—prostate gland—prostate cancer	0.00275	0.0888	CbGeAlD
Vismodegib—CYP3A4—Estradiol—prostate cancer	0.00271	0.0053	CbGbCtD
Vismodegib—ABCB1—Docetaxel—prostate cancer	0.00271	0.00528	CbGbCtD
Vismodegib—SHH—renal system—prostate cancer	0.00268	0.0866	CbGeAlD
Vismodegib—CYP2C19—urine—prostate cancer	0.00236	0.0764	CbGeAlD
Vismodegib—CYP3A4—Prednisone—prostate cancer	0.00233	0.00455	CbGbCtD
Vismodegib—SMO—seminal vesicle—prostate cancer	0.00233	0.0751	CbGeAlD
Vismodegib—SHH—bone marrow—prostate cancer	0.00203	0.0655	CbGeAlD
Vismodegib—ABCB1—Doxorubicin—prostate cancer	0.00202	0.00394	CbGbCtD
Vismodegib—SMO—urethra—prostate cancer	0.00184	0.0595	CbGeAlD
Vismodegib—CYP2C9—urine—prostate cancer	0.00183	0.0592	CbGeAlD
Vismodegib—CYP3A4—Etoposide—prostate cancer	0.00177	0.00346	CbGbCtD
Vismodegib—CYP3A4—Docetaxel—prostate cancer	0.00162	0.00316	CbGbCtD
Vismodegib—CYP3A4—urine—prostate cancer	0.0014	0.0451	CbGeAlD
Vismodegib—SMO—testis—prostate cancer	0.00121	0.0391	CbGeAlD
Vismodegib—CYP3A4—Doxorubicin—prostate cancer	0.00121	0.00236	CbGbCtD
Vismodegib—ORM1—prostate gland—prostate cancer	0.0012	0.0388	CbGeAlD
Vismodegib—Sulfasalazine—TBXAS1—prostate cancer	0.0009	0.201	CrCbGaD
Vismodegib—SMO—lymph node—prostate cancer	0.000878	0.0284	CbGeAlD
Vismodegib—Sorafenib—MAP3K7—prostate cancer	0.000757	0.169	CrCbGaD
Vismodegib—ABCG2—prostate gland—prostate cancer	0.00072	0.0233	CbGeAlD
Vismodegib—Sorafenib—RALBP1—prostate cancer	0.000644	0.144	CrCbGaD
Vismodegib—ORM1—bone marrow—prostate cancer	0.000619	0.02	CbGeAlD
Vismodegib—ABCG2—seminal vesicle—prostate cancer	0.000609	0.0197	CbGeAlD
Vismodegib—CYP2C8—renal system—prostate cancer	0.000505	0.0163	CbGeAlD
Vismodegib—ABCG2—urethra—prostate cancer	0.000482	0.0156	CbGeAlD
Vismodegib—ALB—testis—prostate cancer	0.000464	0.015	CbGeAlD
Vismodegib—ORM1—lymph node—prostate cancer	0.000384	0.0124	CbGeAlD
Vismodegib—Sorafenib—PDGFRB—prostate cancer	0.000379	0.0849	CrCbGaD
Vismodegib—ABCG2—bone marrow—prostate cancer	0.000371	0.012	CbGeAlD
Vismodegib—ABCB1—prostate gland—prostate cancer	0.000355	0.0115	CbGeAlD
Vismodegib—CYP3A4—renal system—prostate cancer	0.000342	0.011	CbGeAlD
Vismodegib—ALB—lymph node—prostate cancer	0.000337	0.0109	CbGeAlD
Vismodegib—CYP2C8—testis—prostate cancer	0.000326	0.0105	CbGeAlD
Vismodegib—ABCG2—testis—prostate cancer	0.000317	0.0102	CbGeAlD
Vismodegib—ABCB1—seminal vesicle—prostate cancer	0.0003	0.0097	CbGeAlD
Vismodegib—Sorafenib—KDR—prostate cancer	0.000287	0.0644	CrCbGaD
Vismodegib—ABCB1—epithelium—prostate cancer	0.000261	0.00843	CbGeAlD
Vismodegib—ABCB1—renal system—prostate cancer	0.000242	0.00782	CbGeAlD
Vismodegib—ABCB1—urethra—prostate cancer	0.000238	0.00768	CbGeAlD
Vismodegib—ABCG2—lymph node—prostate cancer	0.00023	0.00743	CbGeAlD
Vismodegib—Etoricoxib—CYP2E1—prostate cancer	0.000214	0.048	CrCbGaD
Vismodegib—Etoricoxib—CYP2C19—prostate cancer	0.000212	0.0475	CrCbGaD
Vismodegib—Sulfasalazine—CYP3A5—prostate cancer	0.000184	0.0412	CrCbGaD
Vismodegib—ABCB1—bone marrow—prostate cancer	0.000183	0.00591	CbGeAlD
Vismodegib—Tolvaptan—CYP3A4—prostate cancer	0.000178	0.0399	CrCbGaD
Vismodegib—Sorafenib—CYP3A5—prostate cancer	0.000174	0.0388	CrCbGaD
Vismodegib—ABCB1—testis—prostate cancer	0.000156	0.00505	CbGeAlD
Vismodegib—Dysgeusia—Mitoxantrone—prostate cancer	0.000138	0.00117	CcSEcCtD
Vismodegib—Dyspepsia—Goserelin—prostate cancer	0.000137	0.00116	CcSEcCtD
Vismodegib—Back pain—Mitoxantrone—prostate cancer	0.000136	0.00115	CcSEcCtD
Vismodegib—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000136	0.00115	CcSEcCtD
Vismodegib—Asthenia—Ethinyl Estradiol—prostate cancer	0.000136	0.00115	CcSEcCtD
Vismodegib—Decreased appetite—Goserelin—prostate cancer	0.000135	0.00115	CcSEcCtD
Vismodegib—Etoricoxib—CYP3A4—prostate cancer	0.000135	0.0302	CrCbGaD
Vismodegib—Fatigue—Goserelin—prostate cancer	0.000134	0.00114	CcSEcCtD
Vismodegib—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000134	0.00113	CcSEcCtD
Vismodegib—Pruritus—Ethinyl Estradiol—prostate cancer	0.000134	0.00113	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000133	0.00113	CcSEcCtD
Vismodegib—Constipation—Goserelin—prostate cancer	0.000133	0.00113	CcSEcCtD
Vismodegib—Pain—Goserelin—prostate cancer	0.000133	0.00113	CcSEcCtD
Vismodegib—Fatigue—Conjugated Estrogens—prostate cancer	0.000133	0.00113	CcSEcCtD
Vismodegib—Nausea—Bicalutamide—prostate cancer	0.000133	0.00113	CcSEcCtD
Vismodegib—Etoricoxib—PTGS2—prostate cancer	0.000132	0.0296	CrCbGaD
Vismodegib—Pain—Conjugated Estrogens—prostate cancer	0.000132	0.00112	CcSEcCtD
Vismodegib—Constipation—Conjugated Estrogens—prostate cancer	0.000132	0.00112	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—prostate cancer	0.000131	0.00111	CcSEcCtD
Vismodegib—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000129	0.0011	CcSEcCtD
Vismodegib—Arthralgia—Estradiol—prostate cancer	0.000129	0.00109	CcSEcCtD
Vismodegib—Myalgia—Estradiol—prostate cancer	0.000129	0.00109	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000128	0.00108	CcSEcCtD
Vismodegib—Gastrointestinal pain—Goserelin—prostate cancer	0.000127	0.00108	CcSEcCtD
Vismodegib—Hypokalaemia—Prednisone—prostate cancer	0.000127	0.00107	CcSEcCtD
Vismodegib—Weight decreased—Docetaxel—prostate cancer	0.000126	0.00107	CcSEcCtD
Vismodegib—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000126	0.00107	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—prostate cancer	0.000125	0.00106	CcSEcCtD
Vismodegib—Abdominal pain—Goserelin—prostate cancer	0.000123	0.00104	CcSEcCtD
Vismodegib—Weight decreased—Capecitabine—prostate cancer	0.000122	0.00104	CcSEcCtD
Vismodegib—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000122	0.00103	CcSEcCtD
Vismodegib—Nervous system disorder—Estradiol—prostate cancer	0.000121	0.00102	CcSEcCtD
Vismodegib—Vomiting—Ethinyl Estradiol—prostate cancer	0.00012	0.00102	CcSEcCtD
Vismodegib—Arthralgia—Mitoxantrone—prostate cancer	0.00012	0.00102	CcSEcCtD
Vismodegib—Myalgia—Mitoxantrone—prostate cancer	0.00012	0.00102	CcSEcCtD
Vismodegib—Skin disorder—Estradiol—prostate cancer	0.00012	0.00101	CcSEcCtD
Vismodegib—Rash—Ethinyl Estradiol—prostate cancer	0.000119	0.00101	CcSEcCtD
Vismodegib—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000119	0.00101	CcSEcCtD
Vismodegib—Alopecia—Etoposide—prostate cancer	0.000119	0.00101	CcSEcCtD
Vismodegib—Sorafenib—CYP2C19—prostate cancer	0.000118	0.0264	CrCbGaD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.000116	0.000982	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—prostate cancer	0.000115	0.000972	CcSEcCtD
Vismodegib—ABCB1—lymph node—prostate cancer	0.000113	0.00366	CbGeAlD
Vismodegib—Back pain—Etoposide—prostate cancer	0.000113	0.00096	CcSEcCtD
Vismodegib—Muscle spasms—Etoposide—prostate cancer	0.000113	0.000954	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000112	0.000952	CcSEcCtD
Vismodegib—Nausea—Ethinyl Estradiol—prostate cancer	0.000112	0.000951	CcSEcCtD
Vismodegib—Asthenia—Goserelin—prostate cancer	0.000112	0.000946	CcSEcCtD
Vismodegib—Skin disorder—Mitoxantrone—prostate cancer	0.000112	0.000946	CcSEcCtD
Vismodegib—Asthenia—Conjugated Estrogens—prostate cancer	0.000111	0.000937	CcSEcCtD
Vismodegib—Pruritus—Goserelin—prostate cancer	0.00011	0.000932	CcSEcCtD
Vismodegib—Connective tissue disorder—Docetaxel—prostate cancer	0.00011	0.000931	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—prostate cancer	0.000109	0.000927	CcSEcCtD
Vismodegib—Pruritus—Conjugated Estrogens—prostate cancer	0.000109	0.000924	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—prostate cancer	0.000109	0.000923	CcSEcCtD
Vismodegib—Weight decreased—Prednisone—prostate cancer	0.000109	0.000923	CcSEcCtD
Vismodegib—Dyspepsia—Estradiol—prostate cancer	0.000109	0.00092	CcSEcCtD
Vismodegib—Decreased appetite—Estradiol—prostate cancer	0.000107	0.000908	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Estradiol—prostate cancer	0.000106	0.000902	CcSEcCtD
Vismodegib—Diarrhoea—Goserelin—prostate cancer	0.000106	0.000902	CcSEcCtD
Vismodegib—Connective tissue disorder—Capecitabine—prostate cancer	0.000106	0.000901	CcSEcCtD
Vismodegib—Fatigue—Estradiol—prostate cancer	0.000106	0.000901	CcSEcCtD
Vismodegib—Pain—Estradiol—prostate cancer	0.000105	0.000893	CcSEcCtD
Vismodegib—Constipation—Estradiol—prostate cancer	0.000105	0.000893	CcSEcCtD
Vismodegib—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000105	0.000893	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000105	0.000887	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—prostate cancer	0.000101	0.000859	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—prostate cancer	0.000101	0.000858	CcSEcCtD
Vismodegib—Dyspepsia—Mitoxantrone—prostate cancer	0.000101	0.000857	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—prostate cancer	0.000101	0.000854	CcSEcCtD
Vismodegib—Gastrointestinal pain—Estradiol—prostate cancer	0.000101	0.000854	CcSEcCtD
Vismodegib—Decreased appetite—Mitoxantrone—prostate cancer	9.99e-05	0.000846	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—prostate cancer	9.96e-05	0.000843	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—prostate cancer	9.92e-05	0.00084	CcSEcCtD
Vismodegib—Fatigue—Mitoxantrone—prostate cancer	9.91e-05	0.000839	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	9.9e-05	0.000839	CcSEcCtD
Vismodegib—Vomiting—Goserelin—prostate cancer	9.89e-05	0.000838	CcSEcCtD
Vismodegib—Alopecia—Docetaxel—prostate cancer	9.88e-05	0.000837	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—prostate cancer	9.85e-05	0.000835	CcSEcCtD
Vismodegib—Pain—Mitoxantrone—prostate cancer	9.83e-05	0.000832	CcSEcCtD
Vismodegib—Constipation—Mitoxantrone—prostate cancer	9.83e-05	0.000832	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—prostate cancer	9.82e-05	0.000832	CcSEcCtD
Vismodegib—Rash—Goserelin—prostate cancer	9.81e-05	0.000831	CcSEcCtD
Vismodegib—Dermatitis—Goserelin—prostate cancer	9.8e-05	0.00083	CcSEcCtD
Vismodegib—Vomiting—Conjugated Estrogens—prostate cancer	9.8e-05	0.00083	CcSEcCtD
Vismodegib—Abdominal pain—Estradiol—prostate cancer	9.75e-05	0.000826	CcSEcCtD
Vismodegib—Malnutrition—Docetaxel—prostate cancer	9.73e-05	0.000825	CcSEcCtD
Vismodegib—Rash—Conjugated Estrogens—prostate cancer	9.72e-05	0.000823	CcSEcCtD
Vismodegib—Dermatitis—Conjugated Estrogens—prostate cancer	9.71e-05	0.000822	CcSEcCtD
Vismodegib—Alopecia—Capecitabine—prostate cancer	9.57e-05	0.00081	CcSEcCtD
Vismodegib—Dysgeusia—Docetaxel—prostate cancer	9.53e-05	0.000807	CcSEcCtD
Vismodegib—Connective tissue disorder—Prednisone—prostate cancer	9.48e-05	0.000803	CcSEcCtD
Vismodegib—Malnutrition—Capecitabine—prostate cancer	9.42e-05	0.000798	CcSEcCtD
Vismodegib—Back pain—Docetaxel—prostate cancer	9.42e-05	0.000798	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mitoxantrone—prostate cancer	9.4e-05	0.000796	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—prostate cancer	9.38e-05	0.000795	CcSEcCtD
Vismodegib—Muscle spasms—Docetaxel—prostate cancer	9.36e-05	0.000793	CcSEcCtD
Vismodegib—Skin disorder—Etoposide—prostate cancer	9.28e-05	0.000787	CcSEcCtD
Vismodegib—Nausea—Goserelin—prostate cancer	9.24e-05	0.000783	CcSEcCtD
Vismodegib—Dysgeusia—Capecitabine—prostate cancer	9.23e-05	0.000782	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—prostate cancer	9.21e-05	0.00078	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—prostate cancer	9.18e-05	0.000778	CcSEcCtD
Vismodegib—Nausea—Conjugated Estrogens—prostate cancer	9.15e-05	0.000775	CcSEcCtD
Vismodegib—Back pain—Capecitabine—prostate cancer	9.12e-05	0.000772	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—prostate cancer	9.12e-05	0.000772	CcSEcCtD
Vismodegib—Abdominal pain—Mitoxantrone—prostate cancer	9.08e-05	0.00077	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	9.08e-05	0.000769	CcSEcCtD
Vismodegib—Muscle spasms—Capecitabine—prostate cancer	9.06e-05	0.000768	CcSEcCtD
Vismodegib—Asthenia—Estradiol—prostate cancer	8.85e-05	0.00075	CcSEcCtD
Vismodegib—Pruritus—Estradiol—prostate cancer	8.73e-05	0.000739	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—prostate cancer	8.52e-05	0.000722	CcSEcCtD
Vismodegib—Alopecia—Prednisone—prostate cancer	8.52e-05	0.000722	CcSEcCtD
Vismodegib—Diarrhoea—Estradiol—prostate cancer	8.44e-05	0.000715	CcSEcCtD
Vismodegib—Malnutrition—Prednisone—prostate cancer	8.39e-05	0.000711	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—prostate cancer	8.31e-05	0.000704	CcSEcCtD
Vismodegib—Myalgia—Docetaxel—prostate cancer	8.29e-05	0.000702	CcSEcCtD
Vismodegib—Arthralgia—Docetaxel—prostate cancer	8.29e-05	0.000702	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—prostate cancer	8.25e-05	0.000699	CcSEcCtD
Vismodegib—Asthenia—Mitoxantrone—prostate cancer	8.25e-05	0.000698	CcSEcCtD
Vismodegib—Fatigue—Etoposide—prostate cancer	8.24e-05	0.000698	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.23e-05	0.000697	CcSEcCtD
Vismodegib—Pain—Etoposide—prostate cancer	8.17e-05	0.000692	CcSEcCtD
Vismodegib—Constipation—Etoposide—prostate cancer	8.17e-05	0.000692	CcSEcCtD
Vismodegib—Myalgia—Capecitabine—prostate cancer	8.02e-05	0.00068	CcSEcCtD
Vismodegib—Arthralgia—Capecitabine—prostate cancer	8.02e-05	0.00068	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.97e-05	0.000675	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—prostate cancer	7.89e-05	0.000668	CcSEcCtD
Vismodegib—Diarrhoea—Mitoxantrone—prostate cancer	7.86e-05	0.000666	CcSEcCtD
Vismodegib—Vomiting—Estradiol—prostate cancer	7.84e-05	0.000664	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—prostate cancer	7.82e-05	0.000662	CcSEcCtD
Vismodegib—Sulfasalazine—PTGS2—prostate cancer	7.79e-05	0.0174	CrCbGaD
Vismodegib—Nervous system disorder—Docetaxel—prostate cancer	7.79e-05	0.00066	CcSEcCtD
Vismodegib—Rash—Estradiol—prostate cancer	7.78e-05	0.000659	CcSEcCtD
Vismodegib—Dermatitis—Estradiol—prostate cancer	7.77e-05	0.000658	CcSEcCtD
Vismodegib—Skin disorder—Docetaxel—prostate cancer	7.72e-05	0.000654	CcSEcCtD
Vismodegib—Abdominal pain—Etoposide—prostate cancer	7.56e-05	0.00064	CcSEcCtD
Vismodegib—Nervous system disorder—Capecitabine—prostate cancer	7.54e-05	0.000639	CcSEcCtD
Vismodegib—Sorafenib—CYP3A4—prostate cancer	7.51e-05	0.0168	CrCbGaD
Vismodegib—Skin disorder—Capecitabine—prostate cancer	7.47e-05	0.000633	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—prostate cancer	7.41e-05	0.000628	CcSEcCtD
Vismodegib—Nausea—Estradiol—prostate cancer	7.33e-05	0.000621	CcSEcCtD
Vismodegib—Vomiting—Mitoxantrone—prostate cancer	7.31e-05	0.000619	CcSEcCtD
Vismodegib—Rash—Mitoxantrone—prostate cancer	7.25e-05	0.000614	CcSEcCtD
Vismodegib—Dermatitis—Mitoxantrone—prostate cancer	7.24e-05	0.000613	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.24e-05	0.000613	CcSEcCtD
Vismodegib—Arthralgia—Prednisone—prostate cancer	7.15e-05	0.000605	CcSEcCtD
Vismodegib—Myalgia—Prednisone—prostate cancer	7.15e-05	0.000605	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.1e-05	0.000601	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.01e-05	0.000594	CcSEcCtD
Vismodegib—Dyspepsia—Docetaxel—prostate cancer	6.99e-05	0.000592	CcSEcCtD
Vismodegib—Decreased appetite—Docetaxel—prostate cancer	6.91e-05	0.000585	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Docetaxel—prostate cancer	6.86e-05	0.000581	CcSEcCtD
Vismodegib—Asthenia—Etoposide—prostate cancer	6.86e-05	0.000581	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—prostate cancer	6.86e-05	0.000581	CcSEcCtD
Vismodegib—Fatigue—Docetaxel—prostate cancer	6.85e-05	0.00058	CcSEcCtD
Vismodegib—Nausea—Mitoxantrone—prostate cancer	6.83e-05	0.000578	CcSEcCtD
Vismodegib—Pain—Docetaxel—prostate cancer	6.79e-05	0.000575	CcSEcCtD
Vismodegib—Constipation—Docetaxel—prostate cancer	6.79e-05	0.000575	CcSEcCtD
Vismodegib—Dyspepsia—Capecitabine—prostate cancer	6.77e-05	0.000574	CcSEcCtD
Vismodegib—Pruritus—Etoposide—prostate cancer	6.76e-05	0.000573	CcSEcCtD
Vismodegib—Nervous system disorder—Prednisone—prostate cancer	6.72e-05	0.000569	CcSEcCtD
Vismodegib—Decreased appetite—Capecitabine—prostate cancer	6.69e-05	0.000566	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—prostate cancer	6.66e-05	0.000565	CcSEcCtD
Vismodegib—Skin disorder—Prednisone—prostate cancer	6.65e-05	0.000564	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Capecitabine—prostate cancer	6.64e-05	0.000562	CcSEcCtD
Vismodegib—Fatigue—Capecitabine—prostate cancer	6.63e-05	0.000562	CcSEcCtD
Vismodegib—Pain—Capecitabine—prostate cancer	6.58e-05	0.000557	CcSEcCtD
Vismodegib—Constipation—Capecitabine—prostate cancer	6.58e-05	0.000557	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—prostate cancer	6.57e-05	0.000556	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—prostate cancer	6.54e-05	0.000554	CcSEcCtD
Vismodegib—Gastrointestinal pain—Docetaxel—prostate cancer	6.5e-05	0.00055	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—prostate cancer	6.43e-05	0.000545	CcSEcCtD
Vismodegib—Back pain—Epirubicin—prostate cancer	6.35e-05	0.000538	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—prostate cancer	6.31e-05	0.000535	CcSEcCtD
Vismodegib—Gastrointestinal pain—Capecitabine—prostate cancer	6.29e-05	0.000533	CcSEcCtD
Vismodegib—Abdominal pain—Docetaxel—prostate cancer	6.28e-05	0.000532	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Prednisone—prostate cancer	6.24e-05	0.000529	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—prostate cancer	6.17e-05	0.000522	CcSEcCtD
Vismodegib—Abdominal pain—Capecitabine—prostate cancer	6.08e-05	0.000515	CcSEcCtD
Vismodegib—Vomiting—Etoposide—prostate cancer	6.08e-05	0.000515	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—prostate cancer	6.07e-05	0.000515	CcSEcCtD
Vismodegib—Dyspepsia—Prednisone—prostate cancer	6.03e-05	0.000511	CcSEcCtD
Vismodegib—Rash—Etoposide—prostate cancer	6.03e-05	0.000511	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—prostate cancer	6.02e-05	0.00051	CcSEcCtD
Vismodegib—Decreased appetite—Prednisone—prostate cancer	5.96e-05	0.000504	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—prostate cancer	5.95e-05	0.000504	CcSEcCtD
Vismodegib—Fatigue—Prednisone—prostate cancer	5.91e-05	0.0005	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—prostate cancer	5.88e-05	0.000498	CcSEcCtD
Vismodegib—Constipation—Prednisone—prostate cancer	5.86e-05	0.000496	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—prostate cancer	5.84e-05	0.000495	CcSEcCtD
Vismodegib—Asthenia—Docetaxel—prostate cancer	5.7e-05	0.000483	CcSEcCtD
Vismodegib—Nausea—Etoposide—prostate cancer	5.68e-05	0.000481	CcSEcCtD
Vismodegib—Pruritus—Docetaxel—prostate cancer	5.62e-05	0.000476	CcSEcCtD
Vismodegib—Gastrointestinal pain—Prednisone—prostate cancer	5.6e-05	0.000475	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—prostate cancer	5.59e-05	0.000473	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—prostate cancer	5.59e-05	0.000473	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.55e-05	0.00047	CcSEcCtD
Vismodegib—Asthenia—Capecitabine—prostate cancer	5.52e-05	0.000467	CcSEcCtD
Vismodegib—Pruritus—Capecitabine—prostate cancer	5.44e-05	0.000461	CcSEcCtD
Vismodegib—Diarrhoea—Docetaxel—prostate cancer	5.44e-05	0.00046	CcSEcCtD
Vismodegib—Abdominal pain—Prednisone—prostate cancer	5.42e-05	0.000459	CcSEcCtD
Vismodegib—Diarrhoea—Capecitabine—prostate cancer	5.26e-05	0.000446	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—prostate cancer	5.25e-05	0.000445	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—prostate cancer	5.2e-05	0.000441	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—prostate cancer	5.17e-05	0.000438	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—prostate cancer	5.17e-05	0.000438	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.14e-05	0.000435	CcSEcCtD
Vismodegib—Vomiting—Docetaxel—prostate cancer	5.05e-05	0.000428	CcSEcCtD
Vismodegib—Rash—Docetaxel—prostate cancer	5.01e-05	0.000424	CcSEcCtD
Vismodegib—Dermatitis—Docetaxel—prostate cancer	5e-05	0.000424	CcSEcCtD
Vismodegib—Asthenia—Prednisone—prostate cancer	4.92e-05	0.000416	CcSEcCtD
Vismodegib—Vomiting—Capecitabine—prostate cancer	4.89e-05	0.000414	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.88e-05	0.000414	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—prostate cancer	4.86e-05	0.000412	CcSEcCtD
Vismodegib—Rash—Capecitabine—prostate cancer	4.85e-05	0.000411	CcSEcCtD
Vismodegib—Pruritus—Prednisone—prostate cancer	4.85e-05	0.000411	CcSEcCtD
Vismodegib—Dermatitis—Capecitabine—prostate cancer	4.85e-05	0.00041	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—prostate cancer	4.82e-05	0.000408	CcSEcCtD
Vismodegib—Nausea—Docetaxel—prostate cancer	4.72e-05	0.0004	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—prostate cancer	4.72e-05	0.0004	CcSEcCtD
Vismodegib—Diarrhoea—Prednisone—prostate cancer	4.69e-05	0.000397	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—prostate cancer	4.66e-05	0.000395	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—prostate cancer	4.63e-05	0.000392	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—prostate cancer	4.62e-05	0.000391	CcSEcCtD
Vismodegib—Pain—Epirubicin—prostate cancer	4.58e-05	0.000388	CcSEcCtD
Vismodegib—Constipation—Epirubicin—prostate cancer	4.58e-05	0.000388	CcSEcCtD
Vismodegib—Nausea—Capecitabine—prostate cancer	4.57e-05	0.000387	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.52e-05	0.000383	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—prostate cancer	4.38e-05	0.000371	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—prostate cancer	4.36e-05	0.00037	CcSEcCtD
Vismodegib—Vomiting—Prednisone—prostate cancer	4.36e-05	0.000369	CcSEcCtD
Vismodegib—Rash—Prednisone—prostate cancer	4.32e-05	0.000366	CcSEcCtD
Vismodegib—Dermatitis—Prednisone—prostate cancer	4.32e-05	0.000366	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—prostate cancer	4.31e-05	0.000365	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.28e-05	0.000363	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—prostate cancer	4.27e-05	0.000362	CcSEcCtD
Vismodegib—Pain—Doxorubicin—prostate cancer	4.24e-05	0.000359	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—prostate cancer	4.24e-05	0.000359	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—prostate cancer	4.24e-05	0.000359	CcSEcCtD
Vismodegib—Nausea—Prednisone—prostate cancer	4.07e-05	0.000345	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—prostate cancer	4.05e-05	0.000343	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—prostate cancer	3.92e-05	0.000332	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—prostate cancer	3.84e-05	0.000326	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—prostate cancer	3.79e-05	0.000321	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—prostate cancer	3.67e-05	0.000311	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—prostate cancer	3.56e-05	0.000301	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—prostate cancer	3.51e-05	0.000297	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—prostate cancer	3.41e-05	0.000289	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—prostate cancer	3.39e-05	0.000287	CcSEcCtD
Vismodegib—Rash—Epirubicin—prostate cancer	3.38e-05	0.000286	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—prostate cancer	3.38e-05	0.000286	CcSEcCtD
Vismodegib—Nausea—Epirubicin—prostate cancer	3.18e-05	0.00027	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—prostate cancer	3.15e-05	0.000267	CcSEcCtD
Vismodegib—Rash—Doxorubicin—prostate cancer	3.13e-05	0.000265	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—prostate cancer	3.12e-05	0.000265	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—prostate cancer	2.94e-05	0.000249	CcSEcCtD
Vismodegib—ALB—Metabolism—CYP1B1—prostate cancer	2.72e-06	2.49e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NCOA2—prostate cancer	2.7e-06	2.47e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKR1C3—prostate cancer	2.68e-06	2.46e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PRKACB—prostate cancer	2.67e-06	2.45e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.66e-06	2.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.66e-06	2.44e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GGT1—prostate cancer	2.65e-06	2.43e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP17A1—prostate cancer	2.64e-06	2.42e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC5A5—prostate cancer	2.63e-06	2.41e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GGT1—prostate cancer	2.63e-06	2.41e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CG—prostate cancer	2.61e-06	2.4e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NCOA1—prostate cancer	2.61e-06	2.39e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.61e-06	2.39e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NCOA1—prostate cancer	2.59e-06	2.38e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP2E1—prostate cancer	2.57e-06	2.36e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC5A5—prostate cancer	2.57e-06	2.36e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP19A1—prostate cancer	2.57e-06	2.35e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP19A1—prostate cancer	2.56e-06	2.34e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.55e-06	2.34e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTA4—prostate cancer	2.55e-06	2.34e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NQO1—prostate cancer	2.54e-06	2.33e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NCOA2—prostate cancer	2.52e-06	2.31e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EP300—prostate cancer	2.51e-06	2.3e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP2E1—prostate cancer	2.51e-06	2.3e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TH—prostate cancer	2.51e-06	2.3e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.49e-06	2.28e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTA2—prostate cancer	2.49e-06	2.28e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NQO1—prostate cancer	2.48e-06	2.28e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP3A4—prostate cancer	2.48e-06	2.27e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—RXRA—prostate cancer	2.48e-06	2.27e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—INS—prostate cancer	2.47e-06	2.27e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.47e-06	2.26e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—RXRA—prostate cancer	2.47e-06	2.26e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.46e-06	2.25e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCG5—prostate cancer	2.46e-06	2.25e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TH—prostate cancer	2.45e-06	2.24e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SRC—prostate cancer	2.44e-06	2.24e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP1B1—prostate cancer	2.44e-06	2.24e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CREBBP—prostate cancer	2.42e-06	2.22e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP3A4—prostate cancer	2.42e-06	2.22e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.41e-06	2.21e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.4e-06	2.2e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTA1—prostate cancer	2.4e-06	2.2e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.4e-06	2.2e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—COMT—prostate cancer	2.39e-06	2.19e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP1B1—prostate cancer	2.38e-06	2.18e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—prostate cancer	2.38e-06	2.18e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTP1—prostate cancer	2.38e-06	2.18e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—COMT—prostate cancer	2.38e-06	2.18e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.37e-06	2.18e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NAT2—prostate cancer	2.37e-06	2.18e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTO1—prostate cancer	2.37e-06	2.18e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTP1—prostate cancer	2.36e-06	2.17e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GGT1—prostate cancer	2.36e-06	2.16e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.35e-06	2.15e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ITPR1—prostate cancer	2.34e-06	2.14e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NCOA1—prostate cancer	2.33e-06	2.13e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ITPR1—prostate cancer	2.33e-06	2.13e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NQO1—prostate cancer	2.32e-06	2.13e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GGT1—prostate cancer	2.31e-06	2.11e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.3e-06	2.11e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CD—prostate cancer	2.3e-06	2.11e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP19A1—prostate cancer	2.29e-06	2.1e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.29e-06	2.1e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TH—prostate cancer	2.29e-06	2.1e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—LRP2—prostate cancer	2.28e-06	2.09e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PLCB2—prostate cancer	2.28e-06	2.09e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.28e-06	2.09e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.27e-06	2.08e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NCOA1—prostate cancer	2.27e-06	2.08e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.26e-06	2.07e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.25e-06	2.06e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP19A1—prostate cancer	2.24e-06	2.05e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—P4HB—prostate cancer	2.23e-06	2.05e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.22e-06	2.04e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—RXRA—prostate cancer	2.21e-06	2.03e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMS—prostate cancer	2.21e-06	2.03e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMS—prostate cancer	2.2e-06	2.01e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GSTM1—prostate cancer	2.18e-06	2e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TGFB1—prostate cancer	2.18e-06	2e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GSTM1—prostate cancer	2.17e-06	1.99e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.17e-06	1.99e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NOS3—prostate cancer	2.17e-06	1.99e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—RXRA—prostate cancer	2.16e-06	1.98e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GGT1—prostate cancer	2.15e-06	1.97e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.15e-06	1.97e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—LPL—prostate cancer	2.14e-06	1.96e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—LPL—prostate cancer	2.13e-06	1.95e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—COMT—prostate cancer	2.13e-06	1.95e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTP1—prostate cancer	2.12e-06	1.94e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NCOA1—prostate cancer	2.12e-06	1.94e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.12e-06	1.94e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.09e-06	1.92e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ITPR1—prostate cancer	2.09e-06	1.91e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MED12—prostate cancer	2.08e-06	1.91e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—COMT—prostate cancer	2.08e-06	1.91e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTP1—prostate cancer	2.07e-06	1.9e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.07e-06	1.9e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GNG5—prostate cancer	2.07e-06	1.89e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP1A1—prostate cancer	2.06e-06	1.89e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ERCC2—prostate cancer	2.05e-06	1.88e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.05e-06	1.88e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ERCC2—prostate cancer	2.04e-06	1.87e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ITPR1—prostate cancer	2.04e-06	1.87e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—prostate cancer	2.02e-06	1.85e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—RXRA—prostate cancer	2.02e-06	1.85e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CB—prostate cancer	2e-06	1.84e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOA3—prostate cancer	1.99e-06	1.82e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—prostate cancer	1.98e-06	1.82e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMS—prostate cancer	1.97e-06	1.81e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.96e-06	1.8e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GSTM1—prostate cancer	1.95e-06	1.79e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—COMT—prostate cancer	1.94e-06	1.78e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTP1—prostate cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MTHFR—prostate cancer	1.93e-06	1.77e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMS—prostate cancer	1.93e-06	1.76e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MTHFR—prostate cancer	1.92e-06	1.76e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—LPL—prostate cancer	1.91e-06	1.75e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ITPR1—prostate cancer	1.9e-06	1.74e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GSTM1—prostate cancer	1.9e-06	1.74e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HPGDS—prostate cancer	1.9e-06	1.74e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARA—prostate cancer	1.89e-06	1.74e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.89e-06	1.73e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARA—prostate cancer	1.88e-06	1.73e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.87e-06	1.72e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—LPL—prostate cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—prostate cancer	1.86e-06	1.7e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.84e-06	1.69e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ACHE—prostate cancer	1.84e-06	1.69e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ERCC2—prostate cancer	1.83e-06	1.68e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.82e-06	1.67e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP1A1—prostate cancer	1.8e-06	1.65e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMS—prostate cancer	1.8e-06	1.65e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—prostate cancer	1.8e-06	1.65e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ERCC2—prostate cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CAV1—prostate cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GSTM1—prostate cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CAV1—prostate cancer	1.77e-06	1.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.77e-06	1.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.76e-06	1.61e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—LPL—prostate cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.74e-06	1.6e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—prostate cancer	1.73e-06	1.59e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MTHFR—prostate cancer	1.72e-06	1.58e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.7e-06	1.56e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.69e-06	1.55e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARA—prostate cancer	1.69e-06	1.55e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MTHFR—prostate cancer	1.68e-06	1.54e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ERCC2—prostate cancer	1.67e-06	1.53e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—EP300—prostate cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARA—prostate cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.62e-06	1.49e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CG—prostate cancer	1.61e-06	1.48e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CAV1—prostate cancer	1.59e-06	1.46e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.58e-06	1.45e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MTHFR—prostate cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CAV1—prostate cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARA—prostate cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—INS—prostate cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NQO1—prostate cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—INS—prostate cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.52e-06	1.39e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—prostate cancer	1.52e-06	1.39e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TH—prostate cancer	1.51e-06	1.38e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CREBBP—prostate cancer	1.5e-06	1.38e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CREBBP—prostate cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CAV1—prostate cancer	1.45e-06	1.33e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.45e-06	1.33e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GGT1—prostate cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CD—prostate cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.38e-06	1.27e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—INS—prostate cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NOS3—prostate cancer	1.35e-06	1.23e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CREBBP—prostate cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NOS3—prostate cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—INS—prostate cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—RXRA—prostate cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CREBBP—prostate cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—COMT—prostate cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—INS—prostate cancer	1.25e-06	1.15e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CB—prostate cancer	1.24e-06	1.13e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—prostate cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—prostate cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CREBBP—prostate cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—prostate cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NOS3—prostate cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMS—prostate cancer	1.19e-06	1.09e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NOS3—prostate cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—LPL—prostate cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.11e-06	1.02e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.11e-06	1.02e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.1e-06	1.01e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—prostate cancer	1.1e-06	1.01e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NOS3—prostate cancer	1.1e-06	1e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CB—prostate cancer	1.08e-06	9.92e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—prostate cancer	1.07e-06	9.84e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—prostate cancer	1.07e-06	9.83e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—prostate cancer	1.07e-06	9.79e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTHFR—prostate cancer	1.04e-06	9.5e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—EP300—prostate cancer	1.02e-06	9.39e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—EP300—prostate cancer	1.02e-06	9.33e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARA—prostate cancer	1.02e-06	9.32e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.01e-06	9.27e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—prostate cancer	1e-06	9.19e-06	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—prostate cancer	9.98e-07	9.14e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—prostate cancer	9.59e-07	8.79e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CAV1—prostate cancer	9.56e-07	8.76e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—prostate cancer	9.36e-07	8.57e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—EP300—prostate cancer	9.14e-07	8.38e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—EP300—prostate cancer	8.93e-07	8.18e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—prostate cancer	8.74e-07	8.01e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.71e-07	7.98e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—EP300—prostate cancer	8.34e-07	7.64e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—INS—prostate cancer	8.24e-07	7.55e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CREBBP—prostate cancer	8.07e-07	7.4e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.66e-07	7.01e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—prostate cancer	7.58e-07	6.94e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—prostate cancer	7.54e-07	6.9e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NOS3—prostate cancer	7.23e-07	6.62e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—prostate cancer	6.76e-07	6.2e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.67e-07	6.11e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—prostate cancer	6.61e-07	6.06e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—prostate cancer	6.6e-07	6.05e-06	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—prostate cancer	6.19e-07	5.67e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—prostate cancer	6.17e-07	5.65e-06	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—prostate cancer	6.16e-07	5.64e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—prostate cancer	5.77e-07	5.28e-06	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—prostate cancer	5.53e-07	5.06e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—EP300—prostate cancer	5.5e-07	5.04e-06	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—prostate cancer	5.39e-07	4.94e-06	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—prostate cancer	5.04e-07	4.62e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.07e-07	3.73e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—prostate cancer	3.32e-07	3.04e-06	CbGpPWpGaD
